Neoadjuvant	O
Chemotherapy	O
of	O
Ovarian	B:C0029925
Cancer	I:C0029925
Results	O
in	O
Three	O
Patterns	O
of	O
Tumor	O
-	I:C0079722
Infiltrating	I:C0079722
Lymphocyte	I:C0079722
Response	O
with	O
Distinct	O
Implications	O
for	O
Immunotherapy	O
.	O

Neoadjuvant	O
Chemotherapy	O
of	O
Ovarian	O
Cancer	I:C0029925
Results	O
in	O
Three	O
Patterns	O
of	O
Tumor	B:C0079722
-	I:C0079722
Infiltrating	I:C0079722
Lymphocyte	I:C0079722
Response	O
with	O
Distinct	O
Implications	O
for	O
Immunotherapy	O
.	O

Neoadjuvant	O
Chemotherapy	O
of	O
Ovarian	O
Cancer	I:C0029925
Results	O
in	O
Three	O
Patterns	O
of	O
Tumor	O
-	I:C0079722
Infiltrating	I:C0079722
Lymphocyte	I:C0079722
Response	B:C0301909
with	O
Distinct	O
Implications	O
for	O
Immunotherapy	O
.	O

Neoadjuvant	O
Chemotherapy	O
of	O
Ovarian	O
Cancer	I:C0029925
Results	O
in	O
Three	O
Patterns	O
of	O
Tumor	O
-	I:C0079722
Infiltrating	I:C0079722
Lymphocyte	I:C0079722
Response	O
with	O
Distinct	O
Implications	O
for	O
Immunotherapy	B:C0278348
.	O

Purpose	O
:	O
Some	O
forms	O
of	O
chemotherapy	B:C0392920
can	O
enhance	O
antitumor	O
immunity	O
through	O
immunogenic	O
cell	O
death	I:C0007587
,	O
resulting	O
in	O
increased	O
T	O
-	I:C1155065
cell	I:C1155065
activation	I:C1155065
and	O
tumor	O
infiltration	O
.	O

Purpose	O
:	O
Some	O
forms	O
of	O
chemotherapy	O
can	O
enhance	O
antitumor	O
immunity	B:C0020964
through	O
immunogenic	O
cell	O
death	I:C0007587
,	O
resulting	O
in	O
increased	O
T	O
-	I:C1155065
cell	I:C1155065
activation	I:C1155065
and	O
tumor	O
infiltration	O
.	O

Purpose	O
:	O
Some	O
forms	O
of	O
chemotherapy	O
can	O
enhance	O
antitumor	O
immunity	O
through	O
immunogenic	O
cell	B:C0007587
death	I:C0007587
,	O
resulting	O
in	O
increased	O
T	O
-	I:C1155065
cell	I:C1155065
activation	I:C1155065
and	O
tumor	O
infiltration	O
.	O

Purpose	O
:	O
Some	O
forms	O
of	O
chemotherapy	O
can	O
enhance	O
antitumor	O
immunity	O
through	O
immunogenic	O
cell	O
death	I:C0007587
,	O
resulting	O
in	O
increased	O
T	B:C1155065
-	I:C1155065
cell	I:C1155065
activation	I:C1155065
and	O
tumor	O
infiltration	O
.	O

Such	O
effects	O
could	O
potentially	O
sensitize	O
tumors	B:C0027651
to	O
immunotherapies	O
,	O
including	O
checkpoint	O
blockade	I:C1155873
.	O

Such	O
effects	O
could	O
potentially	O
sensitize	O
tumors	O
to	O
immunotherapies	B:C0278348
,	O
including	O
checkpoint	O
blockade	I:C1155873
.	O

Such	O
effects	O
could	O
potentially	O
sensitize	O
tumors	O
to	O
immunotherapies	O
,	O
including	O
checkpoint	B:C1155873
blockade	I:C1155873
.	O

We	O
investigated	O
whether	O
platinum	B:C0032207
-	O
and	O
taxane	O
-	O
based	O
chemotherapy	O
for	O
ovarian	O
cancer	I:C0029925
induces	O
immunologic	O
changes	O
consistent	O
with	O
this	O
possibility	O
.	O

We	O
investigated	O
whether	O
platinum	O
-	O
and	O
taxane	B:C0215136
-	O
based	O
chemotherapy	O
for	O
ovarian	O
cancer	I:C0029925
induces	O
immunologic	O
changes	O
consistent	O
with	O
this	O
possibility	O
.	O

We	O
investigated	O
whether	O
platinum	O
-	O
and	O
taxane	O
-	O
based	O
chemotherapy	B:C0392920
for	O
ovarian	O
cancer	I:C0029925
induces	O
immunologic	O
changes	O
consistent	O
with	O
this	O
possibility	O
.	O

We	O
investigated	O
whether	O
platinum	O
-	O
and	O
taxane	O
-	O
based	O
chemotherapy	O
for	O
ovarian	B:C0029925
cancer	I:C0029925
induces	O
immunologic	O
changes	O
consistent	O
with	O
this	O
possibility	O
.	O

Experimental	B:C0015320
Design	I:C0015320
:	O
Matched	O
pre	O
-	O
and	O
post	O
-	O
neoadjuvant	O
chemotherapy	O
tumor	O
samples	I:C0475358
from	O
26	O
high	O
-	I:C3839280
grade	I:C3839280
serous	I:C3839280
carcinoma	I:C3839280
(	O
high	O
-	I:C3839280
grade	I:C3839280
serous	I:C3839280
carcinoma	I:C3839280
)	O
patients	O
were	O
analyzed	O
by	O
immunohistochemistry	O
(	O
immunohistochemistry	O
)	O
for	O
a	O
large	O
panel	O
of	O
immune	O
cells	I:C0312740
and	O
associated	O
factors	O
.	O

Experimental	O
Design	I:C0015320
:	O
Matched	O
pre	O
-	O
and	O
post	O
-	O
neoadjuvant	O
chemotherapy	O
tumor	B:C0475358
samples	I:C0475358
from	O
26	O
high	O
-	I:C3839280
grade	I:C3839280
serous	I:C3839280
carcinoma	I:C3839280
(	O
high	O
-	I:C3839280
grade	I:C3839280
serous	I:C3839280
carcinoma	I:C3839280
)	O
patients	O
were	O
analyzed	O
by	O
immunohistochemistry	O
(	O
immunohistochemistry	O
)	O
for	O
a	O
large	O
panel	O
of	O
immune	O
cells	I:C0312740
and	O
associated	O
factors	O
.	O

Experimental	O
Design	I:C0015320
:	O
Matched	O
pre	O
-	O
and	O
post	O
-	O
neoadjuvant	O
chemotherapy	O
tumor	O
samples	I:C0475358
from	O
26	O
high	B:C3839280
-	I:C3839280
grade	I:C3839280
serous	I:C3839280
carcinoma	I:C3839280
(	O
high	O
-	I:C3839280
grade	I:C3839280
serous	I:C3839280
carcinoma	I:C3839280
)	O
patients	O
were	O
analyzed	O
by	O
immunohistochemistry	O
(	O
immunohistochemistry	O
)	O
for	O
a	O
large	O
panel	O
of	O
immune	O
cells	I:C0312740
and	O
associated	O
factors	O
.	O

Experimental	O
Design	I:C0015320
:	O
Matched	O
pre	O
-	O
and	O
post	O
-	O
neoadjuvant	O
chemotherapy	O
tumor	O
samples	I:C0475358
from	O
26	O
high	O
-	I:C3839280
grade	I:C3839280
serous	I:C3839280
carcinoma	I:C3839280
(	O
high	B:C3839280
-	I:C3839280
grade	I:C3839280
serous	I:C3839280
carcinoma	I:C3839280
)	O
patients	O
were	O
analyzed	O
by	O
immunohistochemistry	O
(	O
immunohistochemistry	O
)	O
for	O
a	O
large	O
panel	O
of	O
immune	O
cells	I:C0312740
and	O
associated	O
factors	O
.	O

Experimental	O
Design	I:C0015320
:	O
Matched	O
pre	O
-	O
and	O
post	O
-	O
neoadjuvant	O
chemotherapy	O
tumor	O
samples	I:C0475358
from	O
26	O
high	O
-	I:C3839280
grade	I:C3839280
serous	I:C3839280
carcinoma	I:C3839280
(	O
high	O
-	I:C3839280
grade	I:C3839280
serous	I:C3839280
carcinoma	I:C3839280
)	O
patients	O
were	O
analyzed	O
by	O
immunohistochemistry	B:C0021044
(	O
immunohistochemistry	O
)	O
for	O
a	O
large	O
panel	O
of	O
immune	O
cells	I:C0312740
and	O
associated	O
factors	O
.	O

Experimental	O
Design	I:C0015320
:	O
Matched	O
pre	O
-	O
and	O
post	O
-	O
neoadjuvant	O
chemotherapy	O
tumor	O
samples	I:C0475358
from	O
26	O
high	O
-	I:C3839280
grade	I:C3839280
serous	I:C3839280
carcinoma	I:C3839280
(	O
high	O
-	I:C3839280
grade	I:C3839280
serous	I:C3839280
carcinoma	I:C3839280
)	O
patients	O
were	O
analyzed	O
by	O
immunohistochemistry	O
(	O
immunohistochemistry	B:C0021044
)	O
for	O
a	O
large	O
panel	O
of	O
immune	O
cells	I:C0312740
and	O
associated	O
factors	O
.	O

Experimental	O
Design	I:C0015320
:	O
Matched	O
pre	O
-	O
and	O
post	O
-	O
neoadjuvant	O
chemotherapy	O
tumor	O
samples	I:C0475358
from	O
26	O
high	O
-	I:C3839280
grade	I:C3839280
serous	I:C3839280
carcinoma	I:C3839280
(	O
high	O
-	I:C3839280
grade	I:C3839280
serous	I:C3839280
carcinoma	I:C3839280
)	O
patients	O
were	O
analyzed	O
by	O
immunohistochemistry	O
(	O
immunohistochemistry	O
)	O
for	O
a	O
large	O
panel	O
of	O
immune	B:C0312740
cells	I:C0312740
and	O
associated	O
factors	O
.	O

The	O
prognostic	O
significance	O
of	O
post	O
-	O
chemotherapy	B:C0392920
TIL	O
patterns	O
was	O
assessed	O
in	O
an	O
expanded	O
cohort	O
(	O
n	O
=	O
90	O
)	O
.	O

The	O
prognostic	O
significance	O
of	O
post	O
-	O
chemotherapy	O
TIL	B:C0079722
patterns	O
was	O
assessed	O
in	O
an	O
expanded	O
cohort	O
(	O
n	O
=	O
90	O
)	O
.	O

The	O
prognostic	O
significance	O
of	O
post	O
-	O
chemotherapy	O
TIL	O
patterns	O
was	O
assessed	O
in	O
an	O
expanded	O
cohort	B:C0599755
(	O
n	O
=	O
90	O
)	O
.	O

Results	O
:	O
Neoadjuvant	O
chemotherapy	O
was	O
associated	O
with	O
increased	O
densities	O
of	O
CD3	B:C0108779
(+	O
)	O
,	O
CD8	O
(+	O
)	O
,	O
CD8	O
(+	O
)	O
TIA	O
-	I:C1429678
1	I:C1429678
(+	O
)	O
,	O
PD	O
-	I:C2986635
1	I:C2986635
(+	O
)	O
and	O
CD20	O
(+)	O
TIL	O
.	O

Results	O
:	O
Neoadjuvant	O
chemotherapy	O
was	O
associated	O
with	O
increased	O
densities	O
of	O
CD3	O
(+	O
)	O
,	O
CD8	B:C0085358
(+	O
)	O
,	O
CD8	O
(+	O
)	O
TIA	O
-	I:C1429678
1	I:C1429678
(+	O
)	O
,	O
PD	O
-	I:C2986635
1	I:C2986635
(+	O
)	O
and	O
CD20	O
(+)	O
TIL	O
.	O

Results	O
:	O
Neoadjuvant	O
chemotherapy	O
was	O
associated	O
with	O
increased	O
densities	O
of	O
CD3	O
(+	O
)	O
,	O
CD8	O
(+	O
)	O
,	O
CD8	B:C0085358
(+	O
)	O
TIA	O
-	I:C1429678
1	I:C1429678
(+	O
)	O
,	O
PD	O
-	I:C2986635
1	I:C2986635
(+	O
)	O
and	O
CD20	O
(+)	O
TIL	O
.	O

Results	O
:	O
Neoadjuvant	O
chemotherapy	O
was	O
associated	O
with	O
increased	O
densities	O
of	O
CD3	O
(+	O
)	O
,	O
CD8	O
(+	O
)	O
,	O
CD8	O
(+	O
)	O
TIA	B:C1429678
-	I:C1429678
1	I:C1429678
(+	O
)	O
,	O
PD	O
-	I:C2986635
1	I:C2986635
(+	O
)	O
and	O
CD20	O
(+)	O
TIL	O
.	O

Results	O
:	O
Neoadjuvant	O
chemotherapy	O
was	O
associated	O
with	O
increased	O
densities	O
of	O
CD3	O
(+	O
)	O
,	O
CD8	O
(+	O
)	O
,	O
CD8	O
(+	O
)	O
TIA	O
-	I:C1429678
1	I:C1429678
(+	O
)	O
,	O
PD	B:C2986635
-	I:C2986635
1	I:C2986635
(+	O
)	O
and	O
CD20	O
(+)	O
TIL	O
.	O

Results	O
:	O
Neoadjuvant	O
chemotherapy	O
was	O
associated	O
with	O
increased	O
densities	O
of	O
CD3	O
(+	O
)	O
,	O
CD8	O
(+	O
)	O
,	O
CD8	O
(+	O
)	O
TIA	O
-	I:C1429678
1	I:C1429678
(+	O
)	O
,	O
PD	O
-	I:C2986635
1	I:C2986635
(+	O
)	O
and	O
CD20	B:C0054946
(+)	O
TIL	O
.	O

Results	O
:	O
Neoadjuvant	O
chemotherapy	O
was	O
associated	O
with	O
increased	O
densities	O
of	O
CD3	O
(+	O
)	O
,	O
CD8	O
(+	O
)	O
,	O
CD8	O
(+	O
)	O
TIA	O
-	I:C1429678
1	I:C1429678
(+	O
)	O
,	O
PD	O
-	I:C2986635
1	I:C2986635
(+	O
)	O
and	O
CD20	O
(+)	O
TIL	B:C0079722
.	O

Other	O
immune	O
subsets	O
and	O
factors	O
were	O
unchanged	O
,	O
including	O
CD79a	B:C0286618
(+	O
)	O
CD138	O
(+	O
)	O
plasma	O
cells	I:C0032112
,	O
CD68	O
(+	O
)	O
macrophages	O
,	O
and	O
MHC	O
class	I:C0019629
I	I:C0019629
on	O
tumor	O
cells	I:C0597032
.	O

Other	O
immune	O
subsets	O
and	O
factors	O
were	O
unchanged	O
,	O
including	O
CD79a	O
(+	O
)	O
CD138	B:C1609943
(+	O
)	O
plasma	O
cells	I:C0032112
,	O
CD68	O
(+	O
)	O
macrophages	O
,	O
and	O
MHC	O
class	I:C0019629
I	I:C0019629
on	O
tumor	O
cells	I:C0597032
.	O

Other	O
immune	O
subsets	O
and	O
factors	O
were	O
unchanged	O
,	O
including	O
CD79a	O
(+	O
)	O
CD138	O
(+	O
)	O
plasma	B:C0032112
cells	I:C0032112
,	O
CD68	O
(+	O
)	O
macrophages	O
,	O
and	O
MHC	O
class	I:C0019629
I	I:C0019629
on	O
tumor	O
cells	I:C0597032
.	O

Other	O
immune	O
subsets	O
and	O
factors	O
were	O
unchanged	O
,	O
including	O
CD79a	O
(+	O
)	O
CD138	O
(+	O
)	O
plasma	O
cells	I:C0032112
,	O
CD68	B:C0108799
(+	O
)	O
macrophages	O
,	O
and	O
MHC	O
class	I:C0019629
I	I:C0019629
on	O
tumor	O
cells	I:C0597032
.	O

Other	O
immune	O
subsets	O
and	O
factors	O
were	O
unchanged	O
,	O
including	O
CD79a	O
(+	O
)	O
CD138	O
(+	O
)	O
plasma	O
cells	I:C0032112
,	O
CD68	O
(+	O
)	O
macrophages	B:C0024432
,	O
and	O
MHC	O
class	I:C0019629
I	I:C0019629
on	O
tumor	O
cells	I:C0597032
.	O

Other	O
immune	O
subsets	O
and	O
factors	O
were	O
unchanged	O
,	O
including	O
CD79a	O
(+	O
)	O
CD138	O
(+	O
)	O
plasma	O
cells	I:C0032112
,	O
CD68	O
(+	O
)	O
macrophages	O
,	O
and	O
MHC	B:C0019629
class	I:C0019629
I	I:C0019629
on	O
tumor	O
cells	I:C0597032
.	O

Other	O
immune	O
subsets	O
and	O
factors	O
were	O
unchanged	O
,	O
including	O
CD79a	O
(+	O
)	O
CD138	O
(+	O
)	O
plasma	O
cells	I:C0032112
,	O
CD68	O
(+	O
)	O
macrophages	O
,	O
and	O
MHC	O
class	I:C0019629
I	I:C0019629
on	O
tumor	B:C0597032
cells	I:C0597032
.	O

Immunosuppressive	B:C4048329
cell	O
types	O
were	O
also	O
unchanged	O
,	O
including	O
FoxP3	O
(+)	O
PD	O
-	I:C2986635
1	I:C2986635
(+	O
)	O
cells	O
(	O
putative	O
regulatory	O
T	I:C0039198
cells	I:C0039198
)	O
,	O
IDO	O
-	I:C3529891
1	I:C3529891
(+	O
)	O
cells	O
,	O
and	O
PD	O
-	O
L1	O
(+	O
)	O
cells	O
(	O
both	O
macrophages	O
and	O
tumor	O
cells	I:C0597032
)	O
.	O

Immunosuppressive	O
cell	B:C0007634
types	O
were	O
also	O
unchanged	O
,	O
including	O
FoxP3	O
(+)	O
PD	O
-	I:C2986635
1	I:C2986635
(+	O
)	O
cells	O
(	O
putative	O
regulatory	O
T	I:C0039198
cells	I:C0039198
)	O
,	O
IDO	O
-	I:C3529891
1	I:C3529891
(+	O
)	O
cells	O
,	O
and	O
PD	O
-	O
L1	O
(+	O
)	O
cells	O
(	O
both	O
macrophages	O
and	O
tumor	O
cells	I:C0597032
)	O
.	O

Immunosuppressive	O
cell	O
types	O
were	O
also	O
unchanged	O
,	O
including	O
FoxP3	B:C4282118
(+)	O
PD	O
-	I:C2986635
1	I:C2986635
(+	O
)	O
cells	O
(	O
putative	O
regulatory	O
T	I:C0039198
cells	I:C0039198
)	O
,	O
IDO	O
-	I:C3529891
1	I:C3529891
(+	O
)	O
cells	O
,	O
and	O
PD	O
-	O
L1	O
(+	O
)	O
cells	O
(	O
both	O
macrophages	O
and	O
tumor	O
cells	I:C0597032
)	O
.	O

Immunosuppressive	O
cell	O
types	O
were	O
also	O
unchanged	O
,	O
including	O
FoxP3	O
(+)	O
PD	B:C2986635
-	I:C2986635
1	I:C2986635
(+	O
)	O
cells	O
(	O
putative	O
regulatory	O
T	I:C0039198
cells	I:C0039198
)	O
,	O
IDO	O
-	I:C3529891
1	I:C3529891
(+	O
)	O
cells	O
,	O
and	O
PD	O
-	O
L1	O
(+	O
)	O
cells	O
(	O
both	O
macrophages	O
and	O
tumor	O
cells	I:C0597032
)	O
.	O

Immunosuppressive	O
cell	O
types	O
were	O
also	O
unchanged	O
,	O
including	O
FoxP3	O
(+)	O
PD	O
-	I:C2986635
1	I:C2986635
(+	O
)	O
cells	B:C0039198
(	O
putative	O
regulatory	O
T	I:C0039198
cells	I:C0039198
)	O
,	O
IDO	O
-	I:C3529891
1	I:C3529891
(+	O
)	O
cells	O
,	O
and	O
PD	O
-	O
L1	O
(+	O
)	O
cells	O
(	O
both	O
macrophages	O
and	O
tumor	O
cells	I:C0597032
)	O
.	O

Immunosuppressive	O
cell	O
types	O
were	O
also	O
unchanged	O
,	O
including	O
FoxP3	O
(+)	O
PD	O
-	I:C2986635
1	I:C2986635
(+	O
)	O
cells	O
(	O
putative	O
regulatory	B:C0039198
T	I:C0039198
cells	I:C0039198
)	O
,	O
IDO	O
-	I:C3529891
1	I:C3529891
(+	O
)	O
cells	O
,	O
and	O
PD	O
-	O
L1	O
(+	O
)	O
cells	O
(	O
both	O
macrophages	O
and	O
tumor	O
cells	I:C0597032
)	O
.	O

Immunosuppressive	O
cell	O
types	O
were	O
also	O
unchanged	O
,	O
including	O
FoxP3	O
(+)	O
PD	O
-	I:C2986635
1	I:C2986635
(+	O
)	O
cells	O
(	O
putative	O
regulatory	O
T	I:C0039198
cells	I:C0039198
)	O
,	O
IDO	B:C3529891
-	I:C3529891
1	I:C3529891
(+	O
)	O
cells	O
,	O
and	O
PD	O
-	O
L1	O
(+	O
)	O
cells	O
(	O
both	O
macrophages	O
and	O
tumor	O
cells	I:C0597032
)	O
.	O

Immunosuppressive	O
cell	O
types	O
were	O
also	O
unchanged	O
,	O
including	O
FoxP3	O
(+)	O
PD	O
-	I:C2986635
1	I:C2986635
(+	O
)	O
cells	O
(	O
putative	O
regulatory	O
T	I:C0039198
cells	I:C0039198
)	O
,	O
IDO	O
-	I:C3529891
1	I:C3529891
(+	O
)	O
cells	O
,	O
and	O
PD	O
-	O
L1	O
(+	O
)	O
cells	O
(	O
both	O
macrophages	B:C0024432
and	O
tumor	O
cells	I:C0597032
)	O
.	O

Immunosuppressive	O
cell	O
types	O
were	O
also	O
unchanged	O
,	O
including	O
FoxP3	O
(+)	O
PD	O
-	I:C2986635
1	I:C2986635
(+	O
)	O
cells	O
(	O
putative	O
regulatory	O
T	I:C0039198
cells	I:C0039198
)	O
,	O
IDO	O
-	I:C3529891
1	I:C3529891
(+	O
)	O
cells	O
,	O
and	O
PD	O
-	O
L1	O
(+	O
)	O
cells	O
(	O
both	O
macrophages	O
and	O
tumor	B:C0597032
cells	I:C0597032
)	O
.	O

Hierarchical	B:C1881045
clustering	I:C1881045
revealed	O
three	O
response	O
patterns	O
:	O
(	O
i	O
)	O
TIL	O
(	O
high	O
)	O
tumors	O
showed	O
increases	O
in	O
multiple	O
immune	O
markers	O
after	O
chemotherapy	O
;	O
(	O
ii	O
)	O
TIL	O
(	O
low	O
)	O
tumors	O
underwent	O
similar	O
increases	O
,	O
achieving	O
patterns	O
indistinguishable	O
from	O
the	O
first	O
group	O
;	O
and	O
(	O
iii	O
)	O
TIL	O
(	O
negative	O
)	O
cases	O
generally	O
remained	O
negative	O
.	O

Hierarchical	O
clustering	I:C1881045
revealed	O
three	O
response	O
patterns	O
:	O
(	O
i	O
)	O
TIL	B:C0079722
(	O
high	O
)	O
tumors	O
showed	O
increases	O
in	O
multiple	O
immune	O
markers	O
after	O
chemotherapy	O
;	O
(	O
ii	O
)	O
TIL	O
(	O
low	O
)	O
tumors	O
underwent	O
similar	O
increases	O
,	O
achieving	O
patterns	O
indistinguishable	O
from	O
the	O
first	O
group	O
;	O
and	O
(	O
iii	O
)	O
TIL	O
(	O
negative	O
)	O
cases	O
generally	O
remained	O
negative	O
.	O

Hierarchical	O
clustering	I:C1881045
revealed	O
three	O
response	O
patterns	O
:	O
(	O
i	O
)	O
TIL	O
(	O
high	O
)	O
tumors	B:C0027651
showed	O
increases	O
in	O
multiple	O
immune	O
markers	O
after	O
chemotherapy	O
;	O
(	O
ii	O
)	O
TIL	O
(	O
low	O
)	O
tumors	O
underwent	O
similar	O
increases	O
,	O
achieving	O
patterns	O
indistinguishable	O
from	O
the	O
first	O
group	O
;	O
and	O
(	O
iii	O
)	O
TIL	O
(	O
negative	O
)	O
cases	O
generally	O
remained	O
negative	O
.	O

Hierarchical	O
clustering	I:C1881045
revealed	O
three	O
response	O
patterns	O
:	O
(	O
i	O
)	O
TIL	O
(	O
high	O
)	O
tumors	O
showed	O
increases	O
in	O
multiple	O
immune	O
markers	O
after	O
chemotherapy	O
;	O
(	O
ii	O
)	O
TIL	B:C0079722
(	O
low	O
)	O
tumors	O
underwent	O
similar	O
increases	O
,	O
achieving	O
patterns	O
indistinguishable	O
from	O
the	O
first	O
group	O
;	O
and	O
(	O
iii	O
)	O
TIL	O
(	O
negative	O
)	O
cases	O
generally	O
remained	O
negative	O
.	O

Hierarchical	O
clustering	I:C1881045
revealed	O
three	O
response	O
patterns	O
:	O
(	O
i	O
)	O
TIL	O
(	O
high	O
)	O
tumors	O
showed	O
increases	O
in	O
multiple	O
immune	O
markers	O
after	O
chemotherapy	O
;	O
(	O
ii	O
)	O
TIL	O
(	O
low	O
)	O
tumors	O
underwent	O
similar	O
increases	O
,	O
achieving	O
patterns	O
indistinguishable	O
from	O
the	O
first	O
group	O
;	O
and	O
(	O
iii	O
)	O
TIL	B:C0079722
(	O
negative	O
)	O
cases	O
generally	O
remained	O
negative	O
.	O

Hierarchical	O
clustering	I:C1881045
revealed	O
three	O
response	O
patterns	O
:	O
(	O
i	O
)	O
TIL	O
(	O
high	O
)	O
tumors	O
showed	O
increases	O
in	O
multiple	O
immune	O
markers	O
after	O
chemotherapy	O
;	O
(	O
ii	O
)	O
TIL	O
(	O
low	O
)	O
tumors	O
underwent	O
similar	O
increases	O
,	O
achieving	O
patterns	O
indistinguishable	O
from	O
the	O
first	O
group	O
;	O
and	O
(	O
iii	O
)	O
TIL	O
(	O
negative	B:C0205160
)	O
cases	O
generally	O
remained	O
negative	O
.	O

Hierarchical	O
clustering	I:C1881045
revealed	O
three	O
response	O
patterns	O
:	O
(	O
i	O
)	O
TIL	O
(	O
high	O
)	O
tumors	O
showed	O
increases	O
in	O
multiple	O
immune	O
markers	O
after	O
chemotherapy	O
;	O
(	O
ii	O
)	O
TIL	O
(	O
low	O
)	O
tumors	O
underwent	O
similar	O
increases	O
,	O
achieving	O
patterns	O
indistinguishable	O
from	O
the	O
first	O
group	O
;	O
and	O
(	O
iii	O
)	O
TIL	O
(	O
negative	O
)	O
cases	O
generally	O
remained	O
negative	B:C0205160
.	O

Despite	O
the	O
dramatic	O
increases	O
seen	O
in	O
the	O
first	O
two	O
patterns	O
,	O
post	O
-	O
chemotherapy	B:C0392920
TIL	O
showed	O
limited	O
prognostic	O
significance	O
.	O

Despite	O
the	O
dramatic	O
increases	O
seen	O
in	O
the	O
first	O
two	O
patterns	O
,	O
post	O
-	O
chemotherapy	O
TIL	B:C0079722
showed	O
limited	O
prognostic	O
significance	O
.	O

Conclusions	O
:	O
Chemotherapy	O
augments	O
pre-existing	O
TIL	B:C0079722
responses	O
but	O
fails	O
to	O
relieve	O
major	O
immune	O
-	I:C1840264
suppressive	I:C1840264
mechanisms	I:C1840264
or	O
confer	O
significant	O
prognostic	O
benefit	O
.	O

Conclusions	O
:	O
Chemotherapy	O
augments	O
pre-existing	O
TIL	O
responses	B:C0301909
but	O
fails	O
to	O
relieve	O
major	O
immune	O
-	I:C1840264
suppressive	I:C1840264
mechanisms	I:C1840264
or	O
confer	O
significant	O
prognostic	O
benefit	O
.	O

Conclusions	O
:	O
Chemotherapy	O
augments	O
pre-existing	O
TIL	O
responses	O
but	O
fails	O
to	O
relieve	O
major	O
immune	B:C1840264
-	I:C1840264
suppressive	I:C1840264
mechanisms	I:C1840264
or	O
confer	O
significant	O
prognostic	O
benefit	O
.	O

Our	O
findings	O
provide	O
rationale	O
for	O
multipronged	O
approaches	O
to	O
immunotherapy	B:C0278348
tailored	O
to	O
the	O
baseline	O
features	O
of	O
the	O
tumor	O
microenvironment	O
.	O

